Dr Robert Peach has over 25 years of drug discovery and development experience in the pharmaceutical and biotechnology industry.
In 2009, Dr Peach co-founded Receptos and became chief scientific officer, raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for $7.8B.
Dr Peach held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb where he supported in-licensing, acquisition and venture investments.
His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs. He is also the co-author of 70 scientific publications and book chapters, and 17 patents.
